How would you treat a metastatic lung adenocarcinoma with MET exon 14 skip mutation on ctDNA, negative tissue NGS and PD-L1 of >50%?
The NCCN guidelines regard MET exon 14 skip mutation as an emerging biomarker but no formal recommendation to start crizotinib. If high PD-L1 and unclear if this driver mutation decreases IO effectiveness, what upfront treatment would you recommend?
Community PollStarted
How would you treat upfront a stage IV Lung ADC with MET exon 14 skipping mutation and PD-L1>50%?
148 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Michigan Medical School
Answered on
I would treat this patient with single-agent pembrolizumab. If they had rapidly progressing disease with worsening symptoms or if they were a never smoker, I would favor carboplatin/pemetrexed/pembrolizumab in order to optimize rapidity of response. These recommendations are based on the results of ...
Join for free or sign in to see the full answer